SCHEMBL5803281

SCHEMBL5803281

COc1cc(OC)cc(OS(=O)(=O)c2cc(I)c3occc3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA12 O43570 4/20 0.38
CA2 P00918 4/20 0.38
MAOA P21397 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2A6 P11509 1/20 0.35
TSHR P16473 1/20 0.35
ACHE P22303 1/20 0.35
PDE4A P27815 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CYP2A13 Q16696 1/20 0.35
TUBB4A P04350 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5814581 0.79 HTR6 (0.40) LMNAHTTSMN1; SMN2TDP1CA12
SCHEMBL5803267 0.79 CA1 (0.38) LMNAHTTSMN1; SMN2CA12CA2
SCHEMBL5804656 0.77 KDM4E (0.41) L3MBTL1TSHRCYP1A1
SCHEMBL5806198 0.73 HTR2C (0.44) LMNACYP1A1
SCHEMBL5824219 0.73 HTR2C (0.44) LMNACYP1A1
SCHEMBL5805891 0.73 HTR2C (0.44) LMNACYP1A1
SCHEMBL1062600 0.72 CA1 (0.33) TDP1CA12CA2MAOACYP1A2
SCHEMBL5954926 0.71 MAPT (0.38) LMNAHTTL3MBTL1CA12CA2
SCHEMBL1060725 0.68 TP53 (0.51) LMNASMN1; SMN2TSHRMAPK1
SCHEMBL5689322 0.65 ALOX5 (0.58) SMN1; SMN2CYP1A2CYP3A4MAPK1TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142269-A1 New compounds BIOVITRUM AB (SE) 2006-06-29 US disclosed
WO-2006062481-A1 NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . BIOVITRUM AB (SE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142269-A1 New compounds GPR119, GLP1R, IAPP LMNA 3496/4885HTT 799/4885SMN1; SMN2 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.